

Datasheet: LNK022RPE BATCH NUMBER 167802

| RPE CONJU Kit Conjugation | JGATION KIT Kit ATIONS for 60µ een reported to g within our labo om the originato neral protocol r /protocols. Yes • at for each conj | g antibody work in th oratories, ors. Please recommer No ugation th | he following applic peer-reviewed pu e refer to referenc ndations, please vi Not Determine | blications es indicat isit <u>www.b</u> e d S | or personal ted for further bio- uggested Dilution | | |
|---|--|--|---|--|---|--|--|
| Kit Conjugation 3 CONJUGA This product has be derived from testing communications from information. For general- rad-antibodies.com/ Conjugation Conjugation We recommend that ratio. | Kit ATIONS for 60µ een reported to g within our lab- om the originato neral protocol r /protocols. Yes at for each conj | work in th oratories, ors. Pleas recommer No ugation th | he following applic peer-reviewed pu e refer to referenc ndations, please vi Not Determine | blications es indicat isit <u>www.b</u> e d S | or personal ted for further <u>vio-</u> uggested Dilution | | |
| Conjugation 3 CONJUGA This product has be derived from testing communications fro information. For gen rad-antibodies.com Conjugation We recommend that ratio. | ATIONS for 60µ een reported to g within our labo om the originato neral protocol r /protocols. Yes • at for each conj | work in th oratories, ors. Pleas recommer No ugation th | he following applic peer-reviewed pu e refer to referenc ndations, please vi Not Determine | blications es indicat isit <u>www.b</u> e d S | or personal ted for further <u>vio-</u> uggested Dilution | | |
| 3 CONJUGA 3 CONJUGA This product has be derived from testing communications fro information. For gen rad-antibodies.com Conjugation We recommend that ratio. | ATIONS for 60µ een reported to g within our labo om the originato neral protocol r /protocols. Yes • at for each conj | work in th oratories, ors. Pleas recommer No ugation th | he following applic peer-reviewed pu e refer to referenc ndations, please vi Not Determine | blications es indicat isit <u>www.b</u> e d S | or personal ted for further t <u>io-</u> uggested Dilution | | |
| This product has be derived from testing communications fro information. For gen <u>rad-antibodies.com</u> Conjugation We recommend that ratio. | een reported to g within our lab om the originato neral protocol r /protocols. Yes at for each conj | work in th oratories, ors. Pleas recommer No ugation th | he following applic peer-reviewed pu e refer to referenc ndations, please vi Not Determine | blications es indicat isit <u>www.b</u> e d S | or personal ted for further t <u>io-</u> uggested Dilution | | |
| This product has be derived from testing communications fro information. For gen rad-antibodies.com Conjugation We recommend that ratio. | g within our lab om the originato neral protocol r /protocols. Yes at for each conj | oratories, ors. Pleas recommer No ugation th | peer-reviewed pu e refer to referenc ndations, please vi Not Determine | blications es indicat isit <u>www.b</u> e d S | or personal ted for further bio- uggested Dilution | | |
| This product has be derived from testing communications fro information. For gen rad-antibodies.com Conjugation We recommend that ratio. | g within our lab om the originato neral protocol r /protocols. Yes at for each conj | oratories, ors. Pleas recommer No ugation th | peer-reviewed pu e refer to referenc ndations, please vi Not Determine | blications ces indicat isit <u>www.b</u> d S | or personal ted for further t <u>io-</u> uggested Dilution | | |
| derived from testing communications fro information. For gen rad-antibodies.com Conjugation We recommend that ratio. | g within our lab om the originato neral protocol r /protocols. Yes at for each conj | oratories, ors. Pleas recommer No ugation th | peer-reviewed pu e refer to referenc ndations, please vi Not Determine | blications ces indicat isit <u>www.b</u> d S | or personal ted for further t <u>io-</u> uggested Dilution | | |
| communications fro information. For get rad-antibodies.com Conjugation We recommend that ratio. | om the originato neral protocol r / <u>protocols</u> . Yes • at for each conj | ors. Please ecommer No ugation th | e refer to referenc ndations, please vi Not Determine | es indicat isit <u>www.b</u> ed S | ted for further bio- uggested Dilution | | |
| We recommend that ratio. | ■ at for each conj | ugation th | | | | | |
| We recommend that ratio. | at for each conj | | ne user determines | s the best | antibody:conjugate | | |
| directional covalent | protein. Activation of proprietary reagents within the antibody-label solution results in directional covalent bonding of RPE to the antibody. The LYNX Rapid Conjugation kit® can be used to label small quantities of | | | | | | |
| • | antibody/protein at near neutral pH, allowing a high conjugation efficiency with 100% | | | | | | |
| 1 Vial LYNX Modifie | er reagent | RPE mix | | | | | |
| The following buffer | The following buffer solutions are recommended for preparing the antibody: | | | | | | |
| | | | • | • • | | | |
| | | | | | | | |
| | directional covalen The LYNX Rapid C antibody/protein at antibody recovery. it 3 Vials of 100ug LY 1 Vial LYNX Modifi 1 Vial LYNX Quenc The following buffe 10-50mM amine-fre | directional covalent bonding of RF The LYNX Rapid Conjugation kit® antibody/protein at near neutral pl antibody recovery. | directional covalent bonding of RPE to the a The LYNX Rapid Conjugation kit® can be u antibody/protein at near neutral pH, allowin antibody recovery. 3 Vials of 100ug LYNX lyophilized RPE mix 1 Vial LYNX Modifier reagent 1 Vial LYNX Quencher reagent The following buffer solutions are recomme 10-50mM amine-free buffer (e.g HEPES, M | directional covalent bonding of RPE to the antibody. The LYNX Rapid Conjugation kit® can be used to label small antibody/protein at near neutral pH, allowing a high conjugation antibody recovery. 3 Vials of 100ug LYNX lyophilized RPE mix Vial LYNX Modifier reagent Vial LYNX Quencher reagent The following buffer solutions are recommended for preparing 10-50mM amine-free buffer (e.g HEPES, MES, MOPS and plane) | directional covalent bonding of RPE to the antibody. The LYNX Rapid Conjugation kit® can be used to label small quantities antibody/protein at near neutral pH, allowing a high conjugation efficient antibody recovery. it 3 Vials of 100ug LYNX lyophilized RPE mix 1 Vial LYNX Modifier reagent 1 Vial LYNX Quencher reagent | | |

| | chemicals. Azide (0.02-0.1%), EDTA, up to 50% Glycerol and common non-buffering | | | | |
|----------------------|---|--|--|--|--|
| | salts and sugars have little or no effect on conjugation efficiency. | | | | |
| | Due to the large size of RPE (240kDa), it is recommended that 50-60ug of antibody be used for every 100ug RPE, to ensure a slight RPE molar excess. For optimal results the antibody should be at a concentration of 1mg/ml, with a maximum volume of 60ul and a maximum antibody amount of 60ug. Antibody at a concentration of greater than 1mg/ml requires dilution. Antibody below 1mg/ml can still be used as long as the maximum volume is not exceeded. Using less than the recommended amount of antibody may result in unbound label, but this will be removed during subsequent application wash steps. Antibody below 0.5mg/ml should be concentrated before use with the kit. | | | | |
| Instructions For Use | 1. To the antibody sample add 1ul of the Modifier reagent for every 10ul of antibody and mix gently. | | | | |
| | Pipette the mixed antibody-modifier sample directly onto the LYNX lyophilized mix and gently pipette up and down twice to resuspend. | | | | |
| | Replace cap onto vial and incubate in the dark at room temperature (20-25°C) for 3 hours, or overnight if preferred. | | | | |
| | 4. After incubation, add 1ul of Quencher reagent for every 10ul of antibody used. Leave to stand for 30 minutes before use. | | | | |
| References | 1. Li, X. <i>et al.</i> (2010) Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci U S A. 107: 13010-5. | | | | |
| | Campbell, J.E. <i>et al.</i> (2010) Cellular regulation of blood coagulation: a model for venous stasis. <u>Blood. 116: 6082-91.</u> | | | | |
| | 3. Tighe, R.M. <i>et al.</i> (2011) Ozone Inhalation Promotes CX3CR1-Dependent Maturation of Resident Lung Macrophages That Limit Oxidative Stress and Inflammation. <u>J Immunol.</u> 187: 4800-8. | | | | |
| | 4. Dutertre, C.A. <i>et al.</i> (2008) A novel subset of NK cells expressing high levels of | | | | |
| | inhibitory FcgammaRIIB modulating antibody-dependent function. <u>J Leukoc Biol. 84:</u> <u>1511-20.</u> | | | | |
| | 5. Wielgosz, M.M. et al. (2015) Generation of a lentiviral vector producer cell clone for | | | | |
| | human Wiskott-Aldrich syndrome gene therapy. <u>Mol Ther Methods Clin Dev. 2: 14063.</u> | | | | |
| | 6. Hofer, C.C. <i>et al.</i> (2015) Infection of Mice with Influenza A/WSN/33 (H1N1) Virus Alters | | | | |
| | Alveolar Type II Cell Phenotype. <u>Am J Physiol Lung Cell Mol Physiol. ajplung.00373.2014.</u> 7. Welinder, C. <i>et al.</i> (2015) Cytokeratin 20 improves the detection of circulating tumor | | | | |
| | cells in patients with colorectal cancer. Cancer Lett. 358:43-6. | | | | |
| | 8. Shive, C.L. <i>et al.</i> (2014) Inflammatory cytokines drive CD4+ T-cell cycling and impaired | | | | |
| | responsiveness to interleukin 7: implications for immune failure in HIV disease. J Infect | | | | |
| | <u>Dis. 210: 619-29.</u> | | | | |
| | 9. Hofer, S. <i>et al.</i> (2016) RAGE-mediated inflammation in patients with septic shock. \underline{J} | | | | |
| | Surg Res. 202 (2): 315-27. | | | | |
| | 10. Attatippaholkun, N. <i>et al.</i> (2017) Dengue Virus and Its Relation to Human Glycoprotein IIb/IIIa Revealed by Fluorescence Microscopy and Flow Cytometry. <u>Viral Immunol. 30 (9)</u> : | | | | |
| | 654-61. | | | | |
| | 11. Botha, J. <i>et al.</i> (2022) Lipid-based strategies used to identify extracellular vesicles in | | | | |
| | flow cytometry can be confounded by lipoproteins: Evaluations of annexin V, lactadherin, | | | | |
| | | | | | |
| | | | | | |

| | Cytometry-Based Di 13. Haach, V. <i>et al.</i> (| 23) Evaluating Effects of AIV Infectio fferential Blood Count. <u>Microbiol Spec</u> (2023) A polyvalent virosomal influen: ity in pigs. <u>Virol J. 20 (1): 181.</u> | ctr. 11 (4): e0435122. |
|--------------|--|--|--|
| Storage | is shipped under am receipt, Bio-Rad rec Storage in frost-free undiluted. Avoid rep | philized hygroscopic components that bient conditions with silica packets to ommend that the kit is stored at -20°(freezers is not recommended.This pr eated freezing and thawing. Before o ture to minimize condensation. | avoid exposure to moisture. Of C and protected from moisture. roduct should be stored |
| Guarantee | 12 months from date | e of despatch | |
| Health And S | - , | 0546) | 6 #10548 available at: |
| Licensed Us | Kingdom patent num purchase of this proc right (without the rigl | the methodology of conjugation are p nber 2446088 and associated interna- duct conveys to the buyer the limited, ht to resell repackage or further sublic nake conjugates for research and dev | tional patent applications. The non exclusive non-transferable cense) under these patents to |
| | purchaser cannot se data made using this purchasing licenses at. Endeavour House | ell or otherwise transfer this product, or s product, or its components to a third for diagnostic and other uses may be e, Langford Business Park, Langford DOM. Tel: +44 1865 852 700. E-mail: | d party. Further information on e obtained by contacting Bio-Ra Lane, Kidlington, Oxon. OX5 |
| Regulatory | purchaser cannot se data made using this purchasing licenses at. Endeavour House | s product, or its components to a third for diagnostic and other uses may be e, Langford Business Park, Langford DOM. Tel: +44 1865 852 700. E-mail: | d party. Further information on e obtained by contacting Bio-Ra Lane, Kidlington, Oxon. OX5 |

Printed on 29 Feb 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint